Abstract Disseminated tumor cells (DTCs) are detected early in the disease process in prostate cancer (PCa) patients and can persist after radical prostatectomy. DTCs can remain dormant in patients with no evidence of disease for a prolonged period of time only to recur 10 or more years later. Recent advances in single-cell genomics and transcriptomics have provided much needed insight into DTC biology and cancer dormancy in patients. With the development of new in vitro and preclinical models, researchers recapitulate the clinical events in patients and therefore allow further elucidation of the molecular mechanisms underlying cancer dormancy and escape. In this review, we explore novel ideas on the detection, heterogeneous transcriptomic profiles, molecular and cellular mechanisms of dormancy, and potential mechanisms underlying dormancy escape by DTCs. As such, there is hope that identifying and targeting novel dormancy-associated pathways in patients with residual disease will have significant clinical implications for the treatment of PCa patients in the future.
Introduction
Prostate cancer (PCa) disseminated tumor cells (DTCs) have been detected in patient bone marrow prior to radical prostatectomy (RP) [1, 2] . Based on historic data, depending on pathological stage and grade, 16-29 % of patients who undergo RP experience biochemical recurrence and approximately 80 % of them recur within 5 years [3, 4] . However, many patients remain clinically disease-free for years until an increase in serum prostatespecific antigen (PSA) or overt metastases are detected. Although the majority of patients relapse within 5 years, 1 in 5 men recurs after 5 years, and 1 in 20 recurs after 10 years [3, 4] . In a study by Amling et al., the hazard ratio of developing biochemical recurrence either stayed constant for organ-confined disease or decreased only slightly after the peak recurrence during the first 2 years post-RP [3] . Furthermore, Ahove et al. determined that among men with an undetectable PSA 5 years after RP, Gleason score, extracapsular extension, and seminal vesicle invasion were still significant predictors of subsequent late recurrence [5] .
These data raise many questions concerning the prolonged disease relapse such as the following: Can we determine which patients harbor dormant DTCs? What are the DTCs doing during that period of dormancy? What triggers dormant DTCs to regrow? Can we target dormant DTCs with novel therapies when they are held in the quiescent state? In this review, we will address the most updated advances in the detection of DTCs and reveal the heterogeneous nature of DTCs at a single-cell transcriptomic level. We will also discuss emerging hypotheses underlying PCa dormancy and its escape. Finally, the important clinical implications of dormant DTCs in PCa will be evaluated.
Detection of DTCs
The persistence and implications of DTCs are still not completely understood. Our recent study reported detection of DTCs in the bone marrow of PCa patients who have no evidence of disease (NED) for up to 18 years after surgery [6] . Controversies persist in whether the detection of PCa DTCs pre-or post-surgery correlates with clinical parameters or outcomes, partly due to the lack of standardized methodologies to detect DTCs [7, 8] . In the past, detection and analysis of DTCs have been limited by technology. Bone marrow aspirates were analyzed initially for PSA mRNA expression [9] [10] [11] , but this approach relies on the cells being PSA-positive. PSMA is another PCa-associated marker, but it is also expressed by endothelial cells in cancer [12] ; therefore, it would have to be used in combination with other epithelial markers like EpCAM or pan-cytokeratin (CK) for DTC detection. Later on, DTCs were detected using antibodies against pan-CK/ EpCAM on bone marrow aspirates by immunocytochemistry [13] . Until recently, we and others used antibody-conjugated magnetic beads to further enrich for CD45-negative and CK/ EpCAM-positive cells for molecular analysis in individual DTC [1, 2] . More recently, advances in single-cell technology have provided whole genomic and transcriptomic analyses of one cell [6, [14] [15] [16] and demonstrated the heterogeneity as well as the plasticity of individual DTC.
However, single DTC analysis has its limitations. This approach relied on the successful identification of DTCs using epithelial markers including cytokeratin (CK) or epithelial cell adhesion molecule (EpCAM). A recent study by Todenhöfer et al. summarized DTC studies that assessed the percentage of positive DTCs detected in PCa patients pre-or post-surgery [8] . The rates of detection ranged from 13to 45 % using pan-CK staining [1, 9, 11, 13, [17] [18] [19] [20] [21] [22] and 72-90 % using EpCAM staining [2, 10] .
Several recent observations may help explain the observed high proportion of EpCAM-positive cells present in the bone marrow even in early disease. Our subsequent study on a single-cell transcriptomic analysis demonstrated that a significant portion of the EpCAM-positive cells expressed a signature associated with erythroid-progenitor-like cells [6, 23, 24 ]. An independent single-cell gene expression study by Gužvić et al. reported an interesting population of cells that expressed prostate epithelial markers, genomically aberrant, EpCAM-positive but CK8-and CK18-negative, suggesting a potential loss of CK epithelial markers in these DTCs [15] . Therefore, while anti-EpCAM antibody may capture some non-epithelial cells (e.g., erythroidprogenitor-like cells), it may also capture a subgroup of PCa DTCs that are CK8/18-negative. Alternatively, a subgroup of DTCs that displays a neuroendocrine (NE) or a cancer-stem-like cell (CSC) phenotype do not usually express EpCAM but are positive for CK [25, 26] . To further complicate the situation, non-epithelial cells (e.g., plasma cells) in the bone marrow may be CK-positive [27] .
Based on what we have learned to date, we can no longer rely on the use of anti-EpCAM antibodies alone for the identification and isolation of PCa DTCs from the bone marrow. We have known for years that the plasticity of DTCs would result in the loss of detection of some epithelial tumor cells which no longer express routine epithelial markers. Our most recent data from individual cell gene expression complicate this phenomenon further by suggesting that a rare population of non-epithelial cells in the bone marrow also expresses EpCAM. These two biological sources of error prompt us to urge the field to use a more robust cocktail of antibodies to identify and capture DTCs which have lost EpCAM expression and to identify those rare EpCAM-positive bone marrow progenitor cells as non-DTCs. For example, to include NE cells or CSCs which may well be within the DTC population, one could add to the cocktail antibodies that target NE markers like chromogranin A [25, 28] , synaptophysin [25] , and neuron-specific enolase [29] , and CSC markers like CD44 [26] . With future advances in single-cell technology, coupled genomic and transcriptomic analysis, and multispectral imaging will allow a more complete definition of molecular profiles of DTCs with the range of phenotypes observed in PCa.
The transcriptomic profile of DTCs is heterogeneous in patients
To understand the biology behind the DTCs and its relation to tumor dormancy, we [6, 30] and others [15] recently profiled single DTCs in the bone marrow of PCa patients at different stages of disease progression. DTCs displayed high intra-and inter-patient heterogeneity [6, 15] . Gužvić et al., using a single-cell genomic and gene expression analysis, reported that the genomically aberrant DTCs isolated from PCa patients regardless of the metastatic status were highly plastic [15] . Furthermore, a global gene expression analysis on DTCs isolated from PCa NED patients 7-18 years post-RP was compared with that from patients with advanced disease (i.e,. biochemical recurrence or known bone metastasis) in an attempt to uncover clinical dormancy-associated gene signatures [6] . Interestingly, we identified two groups of DTCs in individual patients with advanced disease, and the DTCs in one of these groups display a gene expression pattern similar to that of those isolated from patients with NED [6] . This single DTC analysis suggests that at least two populations of ADV DTCs co-exist in the same microenvironment. While the microenvironment is permissive for the development of bone metastasis, clearly not all DTCs entering the bone form metastasis suggesting these cells enter a dormant/quiescent state.
Molecular and cellular mechanisms of PCa dormancy
We define a dormant cell as one that remains in a quiescent state but has the potential to proliferate. PCa cell dormancy and its reactivation may be governed by cell intrinsic factors or cues from the microenvironment. Thus, signals from the microenvironment may alter the molecular and cellular pathways of the DTCs which results in a dormant or proliferating phenotype.
Tumor microenvironment
Tumor microenvironments contain a multiplicity of cells including tumor cells, target organ cells, CSC, endothelial cells, pericytes, immune inflammatory cells, and cancer-associated fibroblasts among others [31] . Previous studies from Taichman's group have demonstrated that in preclinical models, the hematopoietic stem cell niche in the bone marrow promoted tumor dormancy. Briefly, osteoblast-derived growth arrest specific 6 (GAS6) ligands induced a subset of PCa cells (expressing high GAS6 receptor Axl/Tyro3 ratio) to express a dormant phenotype (Fig. 1) [32] . Additionally, Bdormancyenriched^populations of human PCa cells binding to mouse niche osteoblasts expressed a higher TANK binding kinase 1 level, suggesting at least a subset of PCa cells are under osteoblast-derived growth suppression (Fig. 1) [33] . Examining the perivascular niche, breast cancer (BCa) DTCs have been demonstrated by Ghajar et al. to reside in a dormant state adjacent to mature blood vessels in the lung, bone marrow, and brain, associated with the local endothelial-derived factors such as thrombospondin-1 produced by the mature blood vessels (Fig. 1) [34] . In the same study, apparently dormant DTCs were stimulated to grow when attaching to sprouting microvasculature which secreted periostin and transforming growth factor-beta 1 (TGF-β1) [34] .
CSCs are defined as cells that retain the ability to selfrenew and efficiently seed new tumors [35] . Emerging evidence links the CSC hypothesis with dormancy and metastasis because both CSCs and dormant cells share features like quiescence and immune evasion [36] . On the other hand, a recent publication by Wang et al. comparing mitotic quiescent subpopulations of PCa tumor cells to a rapidly dividing population showed that the quiescent cells were not stem-like, with no expression of CD133 and similar levels of CD44 and integrins α2/β1, when compared to the rapidly dividing population [37] . Their model argues that mitotic quiescence, but not unique Bstemness,^marked the phenotype of bonemetastasis-initiating cells in PCa [38] .
Cellular pathways
Once the DTCs arrive at a foreign microenvironment or niche, they have to adapt before they can proliferate. Notch) [39, 40] . In PCa, BMP7 secreted from bone stromal cells induced senescence through activation of p38 MAPK in human PCa cells as well as CSCs (Fig. 1 ) [41] . Recently, we have shown that in cells derived from PCa patient-derived xenografts, they failed to divide when seeded in low density and these apparently dormant cells showed an upregulated level of TGFB2 [42] . Low cell density also triggered TGFβ/ BMP signaling and redox imbalance to prime cells for dormancy [43] . In a head and neck squamous carcinoma model, TGF-β2 signaling in the bone marrow has been shown to activate p38 MAPK, inducing a high p38/ERK signaling ratio and consequently dormancy (Fig. 1 ) [44] . Similarly, in a BCa dormancy model, Touny et al. have shown that p38 MAPK is inhibitory [45] . Furthermore, they determined that protooncogene tyrosine-protein kinase Src (Src) inhibition can block proliferation (Fig. 1 ), but blocking Src in combination with MEK1/2 which is upstream of ERK 1/2 results in not just growth inhibition, but also apoptosis [45] . Additionally, in BCa, bone marrow stroma has been purported to promote tumor dormancy by reducing CXCL12 and cell cycling in cancer cells (Fig. 1 ) [46, 47] . In contrast, TGFβ2-triggered CXCL12-CXCR4 signaling is crucial for the PCa DTCs to maintain a slow-cycling state in the bone marrow [48] . A recent review has comprehensively summarized the enhanced survival signaling and stress signaling in maintaining dormancy of a cancer cell before it is ready to proliferate [40] .
Transcriptomics
Recent advances in single-cell genomics and transcriptomics, and the successful isolation of DTCs from patients provide novel insights into transcriptomes of PCa DTCs and dormancy. PCa DTCs isolated from the bone marrow of NED patients for 7-18 years post-RP displayed higher expression of the dormancy-associated markers including NR2F1 and TGFB2 than those from patients with biochemical recurrence or bone metastasis ( Fig. 1 ) [30] . Global transcriptomic comparison between DTCs from these two groups of patients revealed a deregulation in the p38 stress response pathway, suggesting that the p38 pathway may play a role in regulating PCa DTC dormancy in the patient bone marrow [6] . Furthermore, cell culture experiments showed a consistent upregulation of TGFB2 gene expression among apparently dormant cells isolated from three PCa patient-derived xenograft models [42] .
Epigenetics
The tumor microenvironment and cellular pathways potentially alter the epigenetics of a cell. A recent review by Crea et al.
proposes that cancer dormancy is a non-genetic disease driven by flexible epigenetic and non-coding interactome [49] . In head and neck squamous carcinoma, Sosa et al. demonstrated that the established dormancy-inducing gene NR2F1 was regulated by histone modifications and was upregulated by 5-azacytidine (a DNA demethylating agent) followed by retinoic acid (Fig. 1 ) [30] . DNA demethylation and histone acetylation has also recently been shown to upregulate the anti-angiogenic gene tissue inhibitor of metalloproteinases-3 (TIMP3) and E-cadherin (CDH1) during ovarian cancer dormancy (Fig. 1) [50] .
MicroRNAs
Emerging evidence supports the role of microRNAs (miRNAs) in the switch of the tumor from a dormant to a fast-growing phenotype. Recently, an unbiased approach has identified miRNAs (e.g., miR-138 and miR-246) as drivers of metastatic reactivation of BCa in the lung in vivo [51] . In multiple cancers, Almog et al. showed that the loss of a set of dormancy-associated miRNAs that downregulated antiangiogenic factors such as TIMP3, basic fibroblast growth factor (bFGF), and TGFα resumed the growth of multiple dormant cancer cell types (e.g., BCa, glioblastoma, osteosarcoma, and liposarcoma) [52] . The same group later determined that cell cycle arrest was not involved in the miR-190-expressing dormant glioblastoma [53] . In BCa, CXCL12-specific miRNAs were proposed to be transported from healthy bone marrow stroma to BCa cells via gap junctions, leading to reduced CXCL12 expression and decreased cell proliferation (Fig. 1 ) [46] . In addition, exosomal transfer of miRNAs (e.g., miR-23b) from the bone marrow may promote BCa cell dormancy via suppression of a target cell cycle gene MARCKS [47] . However, these studies were done on healthy bone marrow stroma. Whether dormant cancer cells can be reactivated when cultured in the cancer-associated bone marrow stroma remains unexplored. Studies on the impact of miRNAs on PCa dormancy are not currently available in the literature.
Escaping dormancy
Emerging preclinical and clinical evidence supports the possible role of an unstable bone microenvironment that favors cancer dormancy reactivation and the outgrowth of metastasis. Zoledronic acid, the osteoclast inhibitor, is routinely prescribed to PCa patients with active bone metastasis or skeletal-related complications to dampen bone resorption and limit bone loss in men receiving androgen deprivation therapy [54] . A model of PCa bone metastasis recently revealed that after androgen ablation, the high bone turnover environment increased the outgrowth of DTCs, and this outgrowth was reversed by zoledronic acid [55] . Similarly, the slow-or non-growing BCa cells attached to the matrix produced by osteoblasts resumed growth after the addition of bone remodeling cytokines, TNFα, and interleukin 1-beta [56] . A BCa clinical trial supported that adjuvant zoledronic acid treatment for those patients with DTCs detected during surgery increased progression-free survival [57] , further supporting the potential benefit of inhibiting bone turnover to prevent metastatic outgrowth. Another clinical study in BCa even showed that zoledronic acid contributed to the eradication of DTCs [58] , although in PCa a preclinical study failed to show that zoledronic acid eliminated the preexisting DTCs [37] . Nonetheless, the potential use of zoledronic acid as an adjuvant therapy to androgen deprivation therapy in minimally metastatic PCa patients will be particularly interesting-one would anticipate that it may help patients preserve a more intact bone environment that is unfavorable to the outgrowth of DTCs and therefore prevent the development of bone metastasis. In PCa, reactivating dormant cells at the cellular level has been proposed by two independent groups reporting that high level of CXCR4 was associated with mitotic quiescence [37] or slow cycling [48] . Inhibition of CXCR4 activity reactivated cell proliferation in vitro [48] . However, when these quiescent cells with high CXCR4 were injected into the circulation, the tumorigenicity of the cells in the bone increased in vivo [37] . While it is likely that the high level of CXCR4 simply increases the bone propensity of this PCa cell line PC3-NW1 and hence its outgrowth in the bone, whether or not the increase in CXCR4 level in the PCa cell impacts the dormancy switch in DTCs that are already in the bone marrow remains unexplored.
Recent research supports that dormant cells maintain reversible cell cycle arrest, a low reactive oxygen species state, and a low metabolic state featured with decreased glycolysis, reduced translation rates, and activation of autophagy [59] [60] [61] . Whether a disruption of these dormancymaintaining cellular states will promote metastatic reactivation warrants investigation. Alternatively, tumor senescence could be achieved by switching on a senescence-like program via activation of Ras signaling [62] , suggesting that dormant cells can potentially be converted to senescent-like cells to irreversibly prevent cancer outgrowth.
Clinical implications of dormant DTCs
To assess the burden and biology of minimal residual disease after RP, DTCs residing at distant sites offer a valid surrogate to be sampled. Although the detection of DTCs does not necessarily imply the development of clinically overt metastasis, the presence of DTCs is unarguably a marker for metastatic burden.
With the relative ease of acquisition of DTCs from the bone marrow and the recent advance in technology to molecularly characterize DTCs at a single-cell level, investigation of DTCs by liquid biopsy before the detection of overt metastasis will be attractive to assess individual prognosis and stratify patients at risk to systemic adjuvant anti-cancer therapies [63] . However, we still face two major technical challenges: (1) Molecular characterization of DTC sampling at easily accessible sites like the iliac crest may not represent DTC burden in other osseous tissues or in visceral tissues, and (2) current positive selection of DTCs using EpCAM or CK could lead to misidentification of epithelial cells [23, 24, 27] . We urge the field to improve methods of identifying DTCs using multiple markers, and this improved method should also ideally allow downstream biological characterization of DTCs using genomic and transcriptomic approaches.
The novel molecular and cellular information generated from DTCs in patient specimens will facilitate biomarker discovery and/or clinical diagnosis and prognosis. We propose that the long latency for PCa reactivation is possibly tightly regulated by multiple mechanisms. We may identify actionable targets to prevent metastasis by maintaining cells in a dormant state, driving proliferating cells into dormancy, or eradicating DTCs. To keep or push PCa DTCs toward a dormant state, based on the current literature, one may consider upregulating the p38 stress response pathway, reactivating BMP7 signaling in the bone marrow niche, inhibiting Src, MEK 1/2, or bone turnover, or target the DTCs at the epigenetic or miRNA level. On the other hand, if the enhanced survival pathways identified in other cancers are common to PCa dormancy, it may be possible to eradicate PCa DTCs by inhibiting these pathways. Importantly, we believe we have only explored the tip of the iceberg of what promotes PCa dormancy in patients post-RP. Unraveling the biology behind DTCs and tumor dormancy will allow us to target early disseminated disease, which should be more effective than targeting the late-stage clinically apparent metastasis.
